21.12.2018 • NewsActelionDede Willams

Actelion to Pay $360 Million in DoJ Settlement

Actelion to Pay $360 Million in DoJ Settlement
Actelion to Pay $360 Million in DoJ Settlement

In a settlement with the US Justice Department (DoJ) Actelion Pharmaceuticals, a Johnson & Johnson subsidiary, has agreed to pay $360 million to settle civil claims it used a charity to pay illegal kickbacks to patients in the US Medicare program.

The Swiss drugmaker acquired by J&J in 2017 allegedly used a charitable foundation to help Medicare patients make payments for its high blood pressure drugs.

According to press reports, the settlement is the largest so far in the ongoing US investigation of the use of charitable foundations in the pharmaceutical industry. In December 2017, United Therapeutics said it would pay $210m to settle similar claims.

For patients who qualify, the government-run Medicare program covers much of the cost of prescription drugs, but patients may still be required to make a copayment, which reduces the price drugmakers can charge. 

The DOJ charges that Actelion’s arrangement with the charity violated the False Claims Act. The company effectively set up a proprietary fund to cover the copays of just its own drugs, said the US attorney for the district of Massachusetts.

Actelion did not admit wrongdoing as part of the settlement. The company noted that the case pre-dates its acquisition by Johnson & Johnson.

Meanwhile, the financial fallout continues from the Reuters report that J&J knew for years that its talc-based baby powder could contain trades of asbestos. Several analysts have suggested it could be cheaper to try to settle the many lawsuits – 11,700 at last count – out of court. In a day’s trading after the news broke, the paper lost $40 billion of its value.

Mark Lanier, a lawyer who represented plaintiffs in the nearly $4.7 billion talc verdict against J&J in July, told the network CNBC the company's talc problems “can be resolved for much, much less than” the tens of billions J&J has lost in market. The company has since appealed that verdict.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.